Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 260 participants.

Also called NCT05487261

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 260 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05487261
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05487261. Randomized; double masking; primary purpose treatment. Start 2022-12-13 (actual); primary completion 2025-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction
Acronym
PRESENT-HF
Condition
Heart Failure
Intervention (Drug)
Sacubitril-valsartan
Intervention (Drug)
Enalapril
Intervention (Drug)
placebo
Intervention (Drug)
Placebo
Lead sponsor
Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań (class: other)
Collaborator
Medical Research Agency, Poland (class: other government)
Collaborator
Medical University of Bialystok (class: other)
Collaborator
University of Opole (class: other)
Collaborator
Medical University of Gdansk (class: other)
Collaborator
Medical University of Silesia (class: other)

Record details

Record id
cardio:ct-nct05487261
Content hash
aeec2ab6cd75b2d17920836352776a9d163db9a0e50167927a8065af92eb5e37